Genetic alterations in EGFR, ALK, ROS1, MET, HER2, KIT, BRAF, and germline BRCA1/BRCA2 have been shown to confer survival benefits on patients with certain solid tumors, including non-small cell lung cancer (1, 2), breast cancer (3), and melanoma (4). Here, BRAF is linked to melanoma.